Covidien releases 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug-coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES). In support of this strategy, the company has entered into a five-year agreement with Stentys as an exclusive worldwide distributor of the MiStent SES, except in the United States, Canada, China, South Korea and Japan. Stentys plans to launch MiStent in the first half of 2015 in Europe, followed by many other geographies where they have built a commercial network

ClearFlow Inc. announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial (PRO-ACT), a clinical study evaluating the use of PleuraFlow Active Clearance Technology System to prevent retained blood complications.

KLAS releases scores and analysis regarding solutions for electronic medical record (EMR) interoperability and health information exchanges (HIEs). This, to provide clarity into a market that is cluttered with competing claims.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now